Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA Phase 2 in Cervical Dystonia
NCT02706795Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daxibotulinumtoxinA in cervical dystonia (CD), sponsored by Revance Therapeutics. Primary endpoint: Change from baseline in Toronto Western Spasmodic Torticollis Rating Scale Total Score at 4 weeks. Started Sep 2015; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT02706795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706795.